Similar articles

• Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.

  Tokmakova M, Solomon SD. Tokmakova M, et al. Curr Opin Cardiol. 2006 Jul;21(4):268-72. doi: 10.1097/01.hco.0000231394.79609.24. Curr Opin Cardiol. 2006. PMID: 16755193 Review.
• The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

  McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. McMurray J, et al. J Am Coll Cardiol. 2006 Feb 21;47(4):726-33. doi: 10.1016/j.jacc.2005.09.055. Epub 2006 Jan 26. J Am Coll Cardiol. 2006. PMID: 16487836
• Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.

  Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Reboldi G, et al. J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2. J Hypertens. 2008. PMID: 18550998
• Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?

  Pfeffer MA. Pfeffer MA. J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2 Suppl):S41-3. doi: 10.3317/jraas.2000.056. J Renin Angiotensin Aldosterone Syst. 2000. PMID: 17199221 Review.
• Blocking the renin-angiotensin system: dual- versus mono-therapy.

  Ravandi A, Teo KK. Ravandi A, et al. Expert Rev Cardiovasc Ther. 2009 Jun;7(6):667-74. doi: 10.1586/erc.09.47. Expert Rev Cardiovasc Ther. 2009. PMID: 19505282 Review.